Clinical Trials Logo

Localized Prostate Cancer clinical trials

View clinical trials related to Localized Prostate Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03814252 Active, not recruiting - Clinical trials for Localized Prostate Cancer

Prospective Clinical Safety and Efficacy Study of Lesion-targeted MRI-TULSA for Localized Prostate Cancer

PRO-TULSA-PC
Start date: October 30, 2018
Phase: N/A
Study type: Interventional

Magnetic resonance imaging (MRI) has improved detection of clinically significant prostate cancer (PCa). MRI-guided transurethral ultrasound ablation (MRI-TULSA) system incorporates precise diagnosis and simultaneous ablation of prostate tissue enabling lesion-targeted treatment of PCa. Lesion-based treatment strategy spares surrounding healthy tissues from injury, which may improve the outcome of genitourinary function. This study further investigates the safety and the efficacy of lesion-targeted ablation of MRI-visible biopsy-proven PCa with MRI-TULSA.

NCT ID: NCT03315754 Active, not recruiting - Clinical trials for Localized Prostate Cancer

Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.

Start date: October 2, 2017
Phase: Phase 2
Study type: Interventional

Single center, single-arm, open-label, 60-month follow-up phase IIb clinical trial. Men with localized prostate cancer will receive TOOKAD® Soluble VTP under general anesthesia. To evaluate the absence of biopsy detectable Gleason grade 4 or 5 prostate cancer tumors anywhere in the prostate gland on 12-month, post-treatment biopsy following TOOKAD® Soluble-VTP in men with prostate cancer Gleason score 7(3+4).

NCT ID: NCT02435472 Active, not recruiting - Clinical trials for Localized Prostate Cancer

Active Surveillance Exercise Clinical Trial

ASX
Start date: June 21, 2016
Phase: N/A
Study type: Interventional

This phase 2, open-label, dual-center, two-arm randomized controlled trial (RCT) investigates the effects of 16 weeks of structured aerobic training, relative to usual care (print material with physical activity guidance). Prostate genomic signatures represent the functional activity of all genes in the genome and are converted into genomic risk scores which correspond to the probability of a progression event (chance of having more aggressive disease). A structured exercise program may alter the genomic risk score and improve prediction of aggressive disease.